Ilodecakin. Schering-Plough Corp.

@article{Marshall1999IlodecakinSC,
  title={Ilodecakin. Schering-Plough Corp.},
  author={John Marshall},
  journal={IDrugs : the investigational drugs journal},
  year={1999},
  volume={2 10},
  pages={1045-58}
}
  • John Marshall
  • Published 1999 in IDrugs : the investigational drugs journal
Schering-Plough's interleukin (IL)-10 (ilodecakin) is under investigation for the potential treatment of autoimmune diseases, solid tumors, ulcerative colitis, Crohn's disease and organ transplantation. In June 1996, ilodecakin entered phase II trials for Crohn's disease, ulcerative colitis and rheumatoid arthritis and, as of June 1999 was reported to be in phase III trials for Crohn's disease and rheumatoid arthritis. It has also demonstrated promising effects in the treatment of inflammatory… CONTINUE READING